1. Landes, Jürgen, Barbara Osimani, Roland Poellinger (forthcoming): Epistemology of Causal Inference in Pharmacology. Towards a Framework for the Assessment of Harms. European Journal for Philosophy of Science
  2. Osimani, Barbara and Roland Poellinger: Causal Inference from Computer Simulation: A Protocol for Model Validation. In: Carusi, Annamaria, Blanca Rodriguez, Kevin Burrage (eds.): Validation and Models in Computational Biomedical Science. Progress in Biophysics and Molecular Biology, 2016 (forthcoming)
  3. Samuel Fletcher, Jürgen Landes, and Roland Poellinger (eds.): Special Issue on “Evidence Amalgamation in the Sciences”, Synthese (in production)
  4. Alessandro Demichelis: Drug Safety, Probabilistic Causal Assessment, and Evidence Synthesis, 27–28 January. The Reasoner, Volume 11, Number 3 – March 2017, pages 10-11.
  5. Landes J., Williamson J. Objective Bayesian nets from consistent datasets. In Proceedings of MaxEnt 2015. AIP, 2016. pages 020007-1 – 020007-8. Open Access. Doi: 10.1063/1.4959048
  6. Jürgen Landes and George Masterton. Invariant Equivocation. Erkenntnis, 82: pages 141–167, 2017. SecondOrder. Doi: 10.1007/s10670-016-9810-1.
  7. March 2016: the Journal of Applied Logic published a special issue edited by Jürgen Landes and Jon Williamson
  8. Osimani B. (Forthcoming) Coherence, Consistency, and Causal inference. In Special Issue on “Evidence Amalgamation”, Synthese; edited by Samuel Fletcher, Jürgen Landes and Roland Poellinger.
  9. Osimani B. (2017) The Meaning of Meta-Analyses. In: Osimani B., La Caze A. (eds.) (2017) Uncertainty in Pharmacology: Epistemology, Methods and Decisions”. Springer: Boston Series in Philosophy of Science.
  10. Landes J., Osimani, B. (2017) Methodological Implications of the Variety of Evidence Thesis. Synthese, Special Issue “Medical Knowledge in a Social World”, Holman, B., Garbayo, L., and Bernecker, S (eds.).
  11. Osimani B. (2016) Interview with Glenn Shafer. The Reasoner 10 (6): 44-47.
  12. Osimani B., Mignini F. (2015) Causal Assessment of Pharmaceutical Treatments: Why Standards of Evidence Should not be the Same for Benefits and Harms. Drug Safety, 38 (19): 1-11.
  13. Osimani B. and Russo F. (2015) Bayesianisme objectif et principe de précaution. In Drouet I. (eds), Le bayésianisme auourd’hui. Fondements et pratiques. Matériologiques.
  14. Osimani B. (2014) Safety vs. efficacy assessment of pharmaceuticals: Epistemological rationales and methods. Preventive Medicine Reports, (1): 9-13.
  15. Osimani B. (2014) Causing something to be one way rather than another: Genetic information, causal specificity and the relevance of linear order. Kybernetes, Special Issue on Information: Space, Time, and Identity (DTMD 2013); 43 (6): 865-81.
  16. Osimani B. (2013) Hunting side effects and explaining them: should we reverse evidence hierarchies upside down? Topoi (Special Issue: Evidence and Causality in the Sciences) October
  17. Osimani B. (2013) Until RCT-proven? On the asymmetry of evidence requirements for risk assessment. Journal of Evaluation in Clinical Practice, 19: 454–46.
  18. Osimani B. (2013) The precautionary principle in the pharmaceutical domain: a philosophical enquiry into probabilistic reasoning and risk aversion. Health, Risk and Society, 15 (2): 123-143.
  19. Osimani B. (2013) An epistemic analysis of the precautionary principle. Dilemata: International Journal of Applied Ethics, 11: 149-167.
  20. Osimani B. (2012) Il contributo delle teorie filosofiche della causalità al dibattito sull’informazione genetica. MEDIC, Special issue: Genetic Information. Epistemological, Anthropological and Ethical Issues, 20 (2): 19-46.
  21. Osimani, B. (2012). Genetic Information. Epistemological, Anthropological and Ethical Issues. Editorial. MEDIC, Methodology and Innovation for Clinical Innovation (editorial), 20 (2): 10-18.
  22. Osimani B. (2012) Risk Information Processing and Rational Ignoring in the Health Context. Journal of Socio-Economics 41: 169-179. DOI information: 10.1016/j.socec.2011.10.009
  23. Osimani B. (2011) Per una formalizzazione bayesiana del principio di precauzione. In: E. Pariotti, G. Guerra, M. Piccinni, D. Ruggiu. “Regolamentazione, forme di responsabilità e nanotecnologie” Dipartimento di Diritto comparato dell’Università di Padova – CIGA, Il Mulino.
  24. Osimani B., F. Russo, J. Williamson (2011) Scientific evidence and the law: an objective Bayesian formalisation of the precautionary principle in pharmaceutical regulation, Journal of Philosophy, Science and Law (11).
  25. Osimani B. (2011) Is the precautionary principle risk aversive? An enquiry in the domain of pharmaceutical decisions. Studia Universitatis Babes-Bolyai – Bioethica, LVI, 2: 57-70.
  26. Osimani B. (2010) Pharmaceutical risk communication: sources of uncertainty and legal tools of uncertainty management. Health Risk and Society, October, Volume 12 Issue 5: 453-469.
  27. Osimani B. (2009) Modus tollens probabilized: deductive and inductive methods in medical diagnosis. MEDIC, Methodology and Education for Clinical Innovation, vol. 17 (1-2): 43-59.
  28. Osimani B. (2007) “The epistemic nature of package leaflet information: A contribution to the legal debate on the role of package leaflets in therapeutic consent”. MEDIC Special Issue: Dicember 2007/ April 2008: 72-90.
  29. Osimani B. (2007) Probabilistic information and decision making in the health context : The package leaflet as basis for informed consent. Doctoral Thesis: Università della Svizzera italiana, 2007; 2007COM009 urn:nbn:ch:rero-006-110691.